Literature DB >> 18455292

Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.

Anu Kallio1, Tao Guo, Elisa Lamminen, Jani Seppänen, Lauri Kangas, H Kalervo Väänänen, Pirkko Härkönen.   

Abstract

In the current work, we compared the ability of 17beta-estradiol (E2) and the selective estrogen receptor modulators (SERMs), tamoxifen (Tam), raloxifene (Ral) and ospemifene (Osp) to promote the survival of osteoblast-derived cells against etoposide-induced apoptosis. In order to compare the roles of the two estrogen receptor (ER) isotypes, we created a U2OS human osteosarcoma cell line stably expressing either ERalpha (ERalpha) or ERbeta (ERbeta). Transfection with either of the ERs was able to render the U2OS cells sensitive to E2. We show that E2 opposed etoposide-induced apoptosis and that the effect was mediated via both ER isotypes. The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively. Osp also opposed apoptosis at least in U2OS/ERalpha cells. Tam and Ral were not able to protect against etoposide-induced cell death. In order to evaluate the protective effects of E2 and Osp upon etoposide challenge, we studied the expression of two E2-regulated, osteoblast-produced cytokines, IL-6 and OPG in E2 and SERM-treated U2OS/ERalpha and U2OS/ERbeta cells. Etoposide strongly increased expression of IL-6 and decreased that of OPG. E2 opposed IL-6 increase only in U2OS/ERalpha cells and OPG decrease primarily in ERbeta cells. Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression. E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta. Collectively, our results suggest that the osteoblast protective anti-apoptotic effects of E2 are mediated by both ERalpha and ERbeta but those of Osp primarily by ERalpha. In addition, E2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity. These anti-resorptive effects of E2 and Osp upon etoposide challenge differed from each other and they seemed to be differentially mediated in ERalpha and ERbeta expressing osteoblast-derived U2OS cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455292     DOI: 10.1016/j.mce.2008.03.005

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  20 in total

1.  Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Authors:  Teresa D Elo; Eeva M Valve; Jani A Seppänen; Heikki J Vuorikoski; Sari I Mäkelä; Matti Poutanen; Paula M Kujala; Pirkko L Härkönen
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

3.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

4.  Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.

Authors:  Mony Shuvy; Suzan Abedat; Ronen Beeri; Michael Valitsky; Sameh Daher; Miriam Kott-Gutkowski; Anca Gal-Moscovici; Jacob Sosna; Nalini M Rajamannan; Chaim Lotan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

Review 5.  Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Authors:  Jing Peng; Surojeet Sengupta; V Craig Jordan
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

6.  Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.

Authors:  Ingrid J De Vries-van Leeuwen; Daniel da Costa Pereira; Koen D Flach; Sander R Piersma; Christian Haase; David Bier; Zeliha Yalcin; Rob Michalides; K Anton Feenstra; Connie R Jiménez; Tom F A de Greef; Luc Brunsveld; Christian Ottmann; Wilbert Zwart; Albertus H de Boer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-15       Impact factor: 11.205

Review 7.  Ospemifene: first global approval.

Authors:  Shelley Elkinson; Lily P H Yang
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

8.  Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro".

Authors:  Valéria F Caparbo; Flávia Prada; Clóvis A A Silva; Paula L Regio; Rosa M R Pereira
Journal:  Clin Rheumatol       Date:  2008-08-07       Impact factor: 2.980

9.  Transcriptional activation of insulin-like growth factor binding protein 6 by 17beta-estradiol in SaOS-2 cells.

Authors:  Yu-yan Zhao; Lei Guo; Xiao-juan Zhao; Hong Liu; Tian Lei; Dong-jie Ma; Xiao-yu Gao
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

10.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.